Compare
Immunocore Holdings plc vs Krystal Biotech, Inc. vs Twist Bioscience Corp vs Tarsus Pharmaceuticals, Inc.
| Latest fiscal year | Immunocore Holdings plc IMCR | Krystal Biotech, Inc. KRYS | Twist Bioscience Corp TWST | Tarsus Pharmaceuticals, Inc. TARS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $400.02M | $389.13M | $376.57M | $451.36M |
| Revenue growth (YoY) | +29.0% | +33.9% | +20.3% | +146.7% |
| Gross margin | n/a | n/a | 50.7% (computed) | n/a |
| Operating margin | -11.3% | 41.5% | -36.2% | -15.7% |
| Net margin | -8.9% | 52.6% | -20.6% | -14.7% |
| Net income | -$35.51M | $204.83M | -$77.67M | -$66.42M |
| EPS (Diluted) | -$0.71 | $6.84 | -$1.30 | -$1.59 |
| Operating cash flow | -$10.71M | $200.87M | -$47.63M | -$12.45M |
| Free cash flow | -$15.05M | $188.91M | -$75.63M | -$22.31M |
| Cash & equivalents | $467.71M | $496.30M | $183.05M | $183.64M |
| Total assets | $1.07B | $1.33B | $641.86M | $562.16M |
| Total liabilities | $686.24M | $114.23M | $168.90M | $218.73M |
| Shareholders' equity | $381.03M | $1.22B | $472.96M | $343.43M |
| Return on year-end equity | -9.3% | 16.8% | -16.4% | -19.3% |
| Shares outstanding | 50.69M | 29.19M | 60.63M | 42.55M |
Revenue, most recent five fiscal years
| Fiscal year | Immunocore Holdings plc | Krystal Biotech, Inc. | Twist Bioscience Corp | Tarsus Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $400.02M Ended 2025-12-31 | $389.13M Ended 2025-12-31 | $376.57M Ended 2025-09-30 | $451.36M Ended 2025-12-31 |
| 1 year earlier | $310.20M Ended 2024-12-31 | $290.51M Ended 2024-12-31 | $312.97M Ended 2024-09-30 | $182.95M Ended 2024-12-31 |
| 2 years earlier | $249.43M Ended 2023-12-31 | $50.70M Ended 2023-12-31 | $245.11M Ended 2023-09-30 | $17.45M Ended 2023-12-31 |
| 3 years earlier | $174.36M Ended 2022-12-31 | $0 Ended 2022-12-31 | $203.56M Ended 2022-09-30 | $25.82M Ended 2022-12-31 |
| 4 years earlier | $36.48M Ended 2021-12-31 | $0 Ended 2021-12-31 | $132.33M Ended 2021-09-30 | $57.03M Ended 2021-12-31 |